-
Phase 1/Phase 2
-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Experimental: Part 1A: BMS-986249
Experimental: Part 1B: BMS-986249 + nivolumab (nivo)
Experimental: Part 2A Arm A: BMS-986249 + nivo then nivo
Experimental: Part 2A Arm B: BMS-986249 + nivo
Experimental: Part 2A Arm C: BMS-986249 + nivo
Experimental: Part 2A Arm D: ipilimumab + nivo then nivo
Experimental: Part 2A Arm E: Nivo
Experimental: Part 2A Arm F: BMS-986249 + nivo
Experimental: Part 2B Cohort 1: BMS-986249 + nivo
Experimental: Part 2B Cohort 2: BMS-986249 + nivo
Experimental: Part 2B Cohort 3: BMS-986249 + nivo